Roth Capital Has Negative View of Zimmer Biomet Q2 Earnings

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Research analysts at Roth Capital dropped their Q2 2025 earnings per share (EPS) estimates for shares of Zimmer Biomet in a research note issued to investors on Tuesday, May 6th. Roth Capital analyst J. Wittes now expects that the medical equipment provider will post earnings of $1.79 per share for the quarter, down from their prior forecast of $2.04. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share. Roth Capital also issued estimates for Zimmer Biomet’s Q3 2025 earnings at $1.90 EPS, Q4 2025 earnings at $2.29 EPS, FY2025 earnings at $7.90 EPS, Q1 2026 earnings at $1.81 EPS, Q2 2026 earnings at $2.13 EPS, Q3 2026 earnings at $1.93 EPS, Q4 2026 earnings at $2.47 EPS and FY2026 earnings at $8.34 EPS.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm had revenue of $1.91 billion during the quarter, compared to analysts’ expectations of $1.89 billion. During the same period last year, the company earned $1.94 earnings per share. The business’s revenue was up 1.1% on a year-over-year basis.

Other equities analysts also recently issued reports about the stock. Wells Fargo & Company cut their price objective on shares of Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating on the stock in a report on Tuesday. Raymond James decreased their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an “outperform” rating for the company in a research note on Tuesday. Royal Bank of Canada cut their target price on Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating on the stock in a research note on Tuesday. The Goldman Sachs Group decreased their price target on Zimmer Biomet from $120.00 to $104.00 and set a “neutral” rating for the company in a research report on Tuesday. Finally, Barclays reduced their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $114.15.

Zimmer Biomet Stock Up 1.0 %

ZBH stock opened at $95.07 on Thursday. The firm has a market capitalization of $18.81 billion, a PE ratio of 21.36, a P/E/G ratio of 1.95 and a beta of 0.78. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet has a twelve month low of $89.92 and a twelve month high of $122.25. The stock’s 50 day moving average is $104.61 and its 200-day moving average is $106.17.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors have recently modified their holdings of the company. B. Riley Wealth Advisors Inc. grew its position in Zimmer Biomet by 17.5% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 2,404 shares of the medical equipment provider’s stock worth $260,000 after acquiring an additional 358 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Zimmer Biomet by 67.6% in the fourth quarter. GAMMA Investing LLC now owns 2,298 shares of the medical equipment provider’s stock valued at $243,000 after acquiring an additional 927 shares during the period. Nordea Investment Management AB raised its stake in shares of Zimmer Biomet by 3.9% during the fourth quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider’s stock valued at $1,732,000 after acquiring an additional 609 shares during the last quarter. First Hawaiian Bank boosted its holdings in shares of Zimmer Biomet by 14.0% during the fourth quarter. First Hawaiian Bank now owns 20,400 shares of the medical equipment provider’s stock worth $2,155,000 after purchasing an additional 2,500 shares during the period. Finally, ORG Partners LLC increased its holdings in Zimmer Biomet by 14,497.5% during the 4th quarter. ORG Partners LLC now owns 5,839 shares of the medical equipment provider’s stock valued at $617,000 after purchasing an additional 5,799 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.39% of the stock is owned by insiders.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.01%. The ex-dividend date was Monday, March 31st. Zimmer Biomet’s payout ratio is 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.